Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Neoprobe Corporation (Neoprobe) has appointed Frederick O. Cope to the company as vice president (VP) of pharmaceutical research and clinical development. Cope has most recently served as the assistant director for research and head of program research development for The Ohio State University Comprehensive Cancer Center, The James Cancer Hospital and The Richard J. Solove Research Institute.
Subscribe to our email newsletter
Cope also served for a number of years as the Ernest W. Volwiler Fellow and head, cancer and AIDS research effort for Abbot Laboratories-Ross Division. Cope is active in a number of professional and scientific organizations such as serving as a current Ad Hoc candidate of the FDA scientific advisory panel, a member of Emory University’s informatics advisory board, and as a full member of the American Society of Clinical Oncology. Cope received his BSc from the Delaware Valley College of Science and Agriculture, his MS from Millersville University of Pennsylvania and his Ph.D. from the University of Connecticut.
David Bupp, Neoprobe’s president and chief executive officer, said, “Neoprobe is very pleased to have someone with Dr. Cope’s pharmaceutical development, clinical and regulatory experience join our management team. Fred is joining us at an exciting point in our corporate development as we work through the pivotal clinical trials and prepare for the regulatory submissions to support marketing clearance for Lymphoseek® and as we make visible progress in reinvigorating our development activities related to
RIGScan® CR. We look forward to his contributions to our team and to the success of Neoprobe Corporation.”
Fred Cope, Neoprobe’s vice president of pharmaceutical research and clinical development, said, “I look forward to becoming part of the Neoprobe team and to the approval of the initial applications of Lymphoseek. This successful program will provide a unique and remarkably valuable tool for the benefit of patients, and I believe, set a new standard in intra-operative diagnosis. I look forward to contributing to the Lymphoseek program and supporting Neoprobe’s other development initiatives.”